Designing Biofunctional Dairy Foods: Matrix Structure of Dairy Products in Relation to Lipaemia
DAIRYMAT
DAIRYMAT
Sponsor study identifier
interventional
25
1 country
1
Study Start
September 10, 2018
Actual (reported)Primary Completion
March 21, 2019
Actual (reported)Study Completion
March 21, 2019
Actual (reported)The overall aim of this study is to investigate how dairy products with different structures and textures affect lipid absorption kinetics in the acute postprandial period via blood lipid biochemistry. The study will be conducted as a randomized acute cross-over meal study. Apparently healthy men will be recruited in the study. They will on 4 test days consume the 4 dairy products and blood will be drawn the following 8 hours.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 21, 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 30, 2018
Actual (reported)September 4, 2018
Actual (reported)September 10, 2018
Actual (reported)March 21, 2019
Actual (reported)March 21, 2019
Actual (reported)Triglyceride
The sample size is calculated on this endpoint. Fasting and postprandial concentrations of triglycerides (mmol/L) are measured after intake of a test meal.
0-8 hour
Apolipoprotein B48
Co-primary endpoint. Fasting and postprandial concentrations of apolipoprotein B48 are measured after intake of a test meal.
0-8 hour
Cholesterol (total, LDL and HDL cholesterol)
0-8 hour
Free Fatty Acid (FFA)
0-8 hour
Insulin
0-8 hour
Glucose
0-8 hour
Apolipoproteins
0-8 hour
Paracetamol
0-8 hour
Metabolomics
0-8 hour
Subjective appetite sensation
0-8 hour
Cross-over study (all subjects receive all interventions) * Cheddar cheese * Blended and homogenized cheddar cheese * An analog milk * An analog cheese
If any subjects (against our hypothesis) have indices of metabolic syndrome i.e. raised fasting glucose or TG concentration, secondary analyses will be conducted to assess results without these subjects. All subjects receive all interventions) * Cheddar cheese * Blended and homogenized cheddar cheese * An analog milk * An analog cheese
The reference product is a commercial matured cheddar cheese
A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet
Department of Nutrition, Exercise and Sports
Frederiksberg, 1958, Denmark
Kjolbaek L, Schmidt JM, Rouy E, Jensen KJ, Astrup A, Bertram HC, Hammershoj M, Raben A. Matrix structure of dairy products results in different postprandial lipid responses: a randomized crossover trial. Am J Clin Nutr. 2021 Nov 8;114(5):1729-1742. doi: 10.1093/ajcn/nqab220.
Thogersen R, Lindahl IEI, Khakimov B, Kjolbaek L, Juhl Jensen K, Astrup A, Hammershoj M, Raben A, Bertram HC. Progression of Postprandial Blood Plasma Phospholipids Following Acute Intake of Different Dairy Matrices: A Randomized Crossover Trial. Metabolites. 2021 Jul 14;11(7):454. doi: 10.3390/metabo11070454.
Anne B Raben, prof
University of Copenhagen
25 participants (actual enrollment reported by the registry).
First Submitted
August 30, 2018
First Posted
September 4, 2018
Study Start
September 10, 2018
An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network
This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Schmidt JM, Kjolbaek L, Jensen KJ, Rouy E, Bertram HC, Larsen T, Raben A, Astrup A, Hammershoj M. Influence of type of dairy matrix micro- and macrostructure on in vitro lipid digestion. Food Funct. 2020 Jun 24;11(6):4960-4972. doi: 10.1039/d0fo00785d.
Primary Completion
March 21, 2019
Actual (reported)Study Completion
March 21, 2019
Actual (reported)Last Updated
November 1, 2021
Record last verified: 2021-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: